A multidisciplinary research team led by James Collins, Ph.D., a member of the Wyss Core Faculty at the Massachusetts Institute of Technology (MIT) and Harvard's Wyss Institute for Biologically Inspired Engineering, and put together by clinical fellow Rose Lee, M.D., M.S.P.H., along with Pollock and Dvorin, has developed a highly sensitive diagnostic assay that can be used in the field to identify DNA sequences from all Plasmodium species in both symptomatic and asymptomatic cases of malaria. With the help of the CRISPR-based SHERLOCK system and an optimised 10-minute quick sample preparation technique, the novel malaria diagnostic approach allows for extremely sensitive and specific Plasmodium identification in just 60 minutes using straightforward reporter devices. The publication is in PNAS.
In response to the growing concern of resistance to existing malaria treatments1,2, Novartis and MMV have decided to move ganaplacide/lumefantrine solid dispersion formulation (SDF) into Phase 3 development for the treatment of individuals suffering from acute, uncomplicated Plasmodium falciparum malaria.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5547
Published Date: Jan 18, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving the growth of the market are surge in adoption of latest technology, rise in government initiatives for the awareness regarding malaria, and extreme weather event to increase prevalence of malaria.
The market size of malaria ag rapid testing is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024-2036.
The major players in the market are Wyss Institute, Novartis AG, Alere, Inc., Nectar Lifesciences Ltd., and others.
The hospital chain pharmacy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.